The Lethbridge iGEM team has a history of developing novel targeted delivery methods. In 2014, the Lethbridge team began development of an innovative cell therapy platform designed to non-invasively deliver a therapeutic genetic construct to neural scars to promote functional recovery from stroke, traumatic brain injury, and neurodegenerative disease (for more information, see the 2014 Lethbridge Wiki). Since the 2014 season, two members of the current 2018 Lethbridge team, Aubrey and Zak, have been committed to patenting and commercializing this technology under the start-up, Nomadogen Biotechnologies Inc., which was incorporated in February of 2015.